Adults 18 to 75, any sex, with Atopic Dermatitis. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
To Evaluate the Clinical Efficacy of RPT193 Administered Orally Once Daily (QD) for 16 Weeks to Participants With Moderate-to-severe ADPrimary· 16 weeks
% change in Eczema Area Severity Index (EASI) from baseline at Week 16
Group
Value
95% CI
RPT193 400 mg
-42.2
± 7.57
RPT193 200 mg
-52.3
± 6.10
RPT193 50 mg
-53.1
± 5.56
Placebo
-59.8
± 5
Number of Participants With Treatment Emergent Adverse Events (TEAEs)Secondary· 16 weeks
To evaluate the safety and tolerability of RPT193 administered orally QD for 16 weeks
Group
Value
95% CI
RPT193 400 mg
26
RPT193 200 mg
29
RPT193 50 mg
21
Placebo
18
Adverse events — posted to ClinicalTrials.gov
Time frame: Approximately 16 weeks. In total, 229 participants were randomized: 57 received RPT193 50 mg, 57 received RPT193 200 mg, 59 received RPT193 400 mg, and 56 received placebo..
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
NCT05935332 — Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma
· Phase 2
· terminated
NCT04271514 — A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis
· Phase 1
· completed
Other recruiting trials for Atopic Dermatitis
Currently open trials in the same condition.
NCT07262983 — Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopi
· Phase 1
· recruiting
NCT07445919 — A Clinical Study to Evaluate SM17 for Atopic Dermatitis
· Phase 2
· recruiting
NCT07488065 — A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants
· Phase 1
· recruiting
NCT07467564 — The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatit
· recruiting
NCT07358156 — A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and E
· Phase 1
· recruiting
Other RAPT Therapeutics, Inc. trials
Trials by the same sponsor.
NCT05935332 — Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma
· Phase 2
· terminated
NCT06087978 — Study of RPT193 in Healthy Adult Male Subjects
· Phase 1
· completed
NCT04894994 — FLX475 in Combination With Ipilimumab in Advanced Melanoma
· Phase 2
· terminated
NCT04271514 — A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis
· Phase 1
· completed
NCT03674567 — Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab
· Phase 1, PHASE2
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by RAPT Therapeutics, Inc.
Last refreshed: 23 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05399368.